Condition: ADHD · Sponsor: Axsome Therapeutics, Inc.
This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to \<18 years with ADHD.
This description comes directly from the study's public registry record.
Study Director · 929-618-4421 · akim@axsome.com
Always discuss trial participation with your own doctor first.
| Clinical Research Site | Dothan, Alabama, United States | Recruiting |
| Clinical Research Site | Little Rock, Arkansas, United States | Recruiting |
| Clinical Research Site | Coral Gables, Florida, United States | Recruiting |
| Clinical Research Site | Jacksonville, Florida, United States | Recruiting |
| Clinical Research Site | Maitland, Florida, United States | Recruiting |
| Clinical Research Site | Orlando, Florida, United States | Recruiting |
| Clinical Research Site | Bardstown, Kentucky, United States | Recruiting |
| Clinical Research Site | Memphis, Tennessee, United States | Recruiting |
| Clinical Research Site | Austin, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07717892